Endo International

Endo and SMSNA Launch App to Provide Peyronie's Disease Self-Assessment Tool

Retrieved on: 
Giovedì, Ottobre 27, 2022
Arousal, App, Time, Bankruptcy Code, Peyronie's disease, Phrase, OTC, Patient, Communication, François Gigot de la Peyronie, Private Securities Litigation Reform Act, Sale, Life, Physician, Completeness, Deformity, Penis, COVID-19, Google Play, Plaque, LinkedIn, Endo International, Company, Compliance, Legislation, Knowledge, Director, Research, App store, Forecasting, Risk, App store optimization, Public expenditure, PD, Endo, DRS, Diagnosis, Advertising, Chapter 11, Title 11, United States Code, Uncertainty, Medical device, Pharmaceutical industry, Man, Tursi, Disease

DUBLIN and BURNSVILLE, Minn., Oct. 27, 2022 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) and the Sexual Medicine Society of North America (SMSNA) announced today the launch of a Peyronie's Self-Assessment application, available now in the App Store and Google Play. Peyronie's Disease (PD) is a men's health condition that may affect 1 in 10 men and can lead to a curvature deformity with a plaque that can be felt in the penis.

Key Points: 
  • Men who download the free app may use it to:
    The app is not a diagnostic tool, but men can share the results with their urologist to help the physician evaluate symptoms.
  • The Peyronie's Self-Assessment app will be unveiled during the 23rd Annual Fall Scientific Meeting of SMSNA, taking place October 27-30 in Miami, FL, via an oral presentation on Saturday and a medical booth co-hosted by Endo and SMSNA.
  • SMSNA for Patients was established as SexHealthMatters in 2010 to provide information on a broad range of sexual health conditions.
  • Endo expressly disclaims any intent or obligation to update these forward-looking statements, except as required to do so by law.

Venus Concept Appoints Dr. Hemanth Varghese as President & Chief Business Officer

Retrieved on: 
Martedì, Ottobre 11, 2022
Bausch & Lomb, Securities Act of 1933, Communication, Therapy, Strategy, Bausch, General manager, Growth, Specialization, Medical physics, Concept, Bausch Health, International Pharmaceutical Students' Federation, Annual report, NASDAQ, Securities Exchange Act of 1934, Ophthalmology, CFA, Corporation, Senior, Hair, Company, ARTAS, Doctor of Philosophy, Industry, Corporate development, GLOBE, Endo International, COVID-19, HLS, Solution, Rajiv, Management, Nightclub, Risk management, Western University

TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (Venus Concept or the Company) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. Hemanth Varghese to the position of President & Chief Business Officer, effective October 17, 2022.

Key Points: 
  • TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (Venus Concept or the Company) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. Hemanth Varghese to the position of President & Chief Business Officer, effective October 17, 2022.
  • We are delighted to have Hemanth join Venus Concept at this pivotal time for the Company, said Rajiv De Silva, Chief Executive Officer and Director of Venus Concept.
  • Before joining Venus Concept as President and Chief Business Officer, Dr. Varghese served as Senior Vice President of Strategy & Operations at HLS Therapeutics from 2017 to 2022.
  • Venus Concepts product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve and Venus Viva MD.

Agile Therapeutics Announces Reorganization of Leadership Team

Retrieved on: 
Venerdì, Ottobre 7, 2022
LinkedIn, Marketing, CHC, AstraZeneca, Birth, G&A, Body mass index, Therapy, Parliamentary Information Technology Committee, BMI, Efficiency, Woman, Amy, HCPS, Research, Twitter, LNG, Financial compensation, Partnership, Nasdaq, Professional Football Compensation Committee, Levonorgestrel, Company, Health, Ethinylestradiol, Agile, Endo International, CTV, Skin, GLOBE, M.B.A, Freedom, Management, Birth control, Contraceptive patch

PRINCETON, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it has reorganized and streamlined its executive leadership team to align with its business plan to promote Twirla® (levonorgestrel and ethinyl estradiol) transdermal system growth. As part of the changes, the Company announced the appointment of Amy Welsh to Chief Commercial Officer effective November 1, 2022. Additionally, James P. Tursi, M.D. has informed the Company that he will resign from the Company’s board of directors effective October 7, 2022.

Key Points: 
  • Our focus in 2022 has been on growing Twirla and advancing towards generating positive cash flow, said Agile Therapeutics Chairman and Chief Executive Officer Al Altomari.
  • The changes to our leadership team we are announcing today are expected to help us consolidate the efficiency gains we have made in our operations by streamlining my executive team and maintaining our focus on executing our business plan.
  • In addition to her current responsibilities leading the Twirla marketing team, Ms. Welsh, as Chief Commercial Officer, will assume responsibility for all the Companys commercial functions.
  • Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of todays women.

Venus Concept Announces Appointment of Rajiv De Silva as Chief Executive Officer and Director; Updates Fiscal Year 2022 Revenue Guidance

Retrieved on: 
Lunedì, Ottobre 3, 2022
Venus, Securities Act of 1933, BSE, GLOBE, Securities Exchange Act of 1934, Hair, Bausch Health, Wendell Pritchett, NASDAQ, Stanford University, Princeton University, Dermatology, University, MS, Industry, CEO, McKinsey & Company, Novartis, COVID-19, Annual report, Webcast, Growth, COO, Endo International, Â, Communication, Rajiv, Director, Leadership, Conference, Board, Company, ARTAS, Wharton School of the University of Pennsylvania, Management, Online gambling

The Company also announced the separation of Domenic Serafino as Chief Executive Officer and Director, effective October 2, 2022.

Key Points: 
  • The Company also announced the separation of Domenic Serafino as Chief Executive Officer and Director, effective October 2, 2022.
  • We are excited to have Rajiv join the Company to lead Venus Concept through its next stage of growth and development, said Scott Barry, Chairman and Director of Venus Concept.
  • Updated Fiscal Year 2022 Revenue Guidance:
    In connection with Rajiv De Silva's appointment as Chief Executive Officer, the Company has withdrawn its previously issued revenue guidance for fiscal year 2022, which was last updated on August 12, 2022.
  • Venus Concepts product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve and Venus Viva MD.

Delisting of Securities of Renovare Environmental, Inc.; Endo International plc; Clarus Therapeutics Holdings, Inc.; NewAge, Inc.; and Allena Pharmaceuticals, Inc. from The Nasdaq Stock Market

Retrieved on: 
Martedì, Settembre 13, 2022
Newage, Time, News, Bangladesh Securities and Exchange Commission, Endo International, Delisting, Security (finance), GLOBE, Online gambling, Pharmaceutical industry, Online shopping, Nasdaq

Nasdaq also announced today that it will delist the ordinary shares of Endo International plc.

Key Points: 
  • Nasdaq also announced today that it will delist the ordinary shares of Endo International plc.
  • Endo International plcs shares were suspended on August 26, 2022 and have not traded on Nasdaq since that time.
  • Nasdaq also announced today that it will delist the common stock and warrant 9/9/2026 of Clarus Therapeutics Holdings, Inc. Clarus Therapeutics Holdings, Inc.s securities were suspended on August 31, 2022 and have not traded on Nasdaq since that time.
  • Nasdaq also announced today that it will delist the common stock of Allena Pharmaceuticals, Inc. Allena Pharmaceuticals, Inc.s common stock was suspended on September 8, 2022 and has not traded on Nasdaq since that time.

LynxDx Adds New Executive Leadership

Retrieved on: 
Mercoledì, Settembre 7, 2022
University, Technology, Cancer, PSA, Exact sciences, ANN, Solution, TMPRSS2, Risk assessment, Man, PCA3, ERG, Physician, Endo International, MPS, National accounts, Market access, Health, Prostate-specific antigen, Biotechnology, Risk, Prostate cancer, Genomics, Growth, Urine, Patient, Management, Medical imaging, Pharmaceutical industry

ANN ARBOR, Mich., Sept. 7, 2022 /PRNewswire/ -- LynxDx, developers of the revolutionary MyProstateScore™ (MPS), announces the hiring of Jeremiah Johnson as Vice President of Sales and Shawn Wheeler as Senior Director of Market Access.

Key Points: 
  • "As LynxDx grows and expands, we are excited about these two dynamic individuals joining our team."
  • Johnson brings to LynxDx more than 20 years of award-winning experience in the diagnostic, medical, biotechnology, and pharmaceutical industries.
  • He joins LynxDx from a decade-long progressive career at Exact Sciences, Inc., most recently as National Accounts Manager, Commercial Markets.
  • Using technology developed at the University of Michigan, LynxDx develops innovative diagnostic solutions that can be implemented in a clinical setting.

Federal Circuit Rules in Favor of Eagle Pharmaceuticals in Vasopressin Litigation

Retrieved on: 
Giovedì, Agosto 18, 2022
FDA, Regulation of tobacco by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Kirkland & Ellis, List, United States Court of Appeals for the Federal Circuit, CNS, GLOBE, Catecholamine, Forward-looking statement, Phrase, Failure, Abbreviated New Drug Application, Private Securities Litigation Reform Act, SEC, District, European Medicines Agency, Virginia General District Court, Research, Annual report, Security (finance), Compliance, ANDA, LLP, Douglas v. U.S. District Court ex rel Talk America, Marketing, Patient, Hypotension, Company, COVID-19, Drug development, District court, Par, Sepsis, Genta (company), Blood pressure, Endo International, Vasodilatory shock, Eagle, Nasdaq, Food, Online gambling, Pharmaceutical industry

Par previously sued Eagle in 2018, alleging infringement of several of its patents and a trial was held in July 2021.

Key Points: 
  • Par previously sued Eagle in 2018, alleging infringement of several of its patents and a trial was held in July 2021.
  • The District Court held that Eagle did not infringe on any of Pars patents, and Par appealed.
  • Oral arguments were held before the Federal Circuit in July 2022.
  • Today, the Federal Circuit issued its decision rejecting Pars arguments and affirming the District Courts finding of non-infringement.

KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications

Retrieved on: 
Martedì, Agosto 9, 2022
FDA, Regulation of tobacco by the U.S. Food and Drug Administration, ADHD, SDX, Glycogen storage disease, Ageing, NDA, Endo International, CEO, CNS, GLOBE, Growth, YouTube, Facebook, Benzhydrocodone, Corporate communication, West Virginia University, Niemann–Pick disease, Narcolepsy, Patient, Hydrocodone, Company, Twitter, Acquisition, Central nervous system, NPC, Awareness, Idiopathic hypersomnia, Nasdaq, Medarex, Bristol Myers Squibb, Virginia University, IH, LinkedIn, Paracetamol, Food, KMPH, Pharmaceutical industry, Management

We are very pleased to welcome Nichol to KemPharm and look forward to benefitting from her more than 20 years experience developing investor relations and corporate communications strategies in the biopharmaceutical industry, stated Travis Mickle, Ph.D., President and CEO of KemPharm.

Key Points: 
  • We are very pleased to welcome Nichol to KemPharm and look forward to benefitting from her more than 20 years experience developing investor relations and corporate communications strategies in the biopharmaceutical industry, stated Travis Mickle, Ph.D., President and CEO of KemPharm.
  • Prior to joining KemPharm, Ms. Ochsner served as Executive Vice President of Investor Relations and Corporate Communications with Statera Biopharma.
  • Previously, Ms. Ochsner served as Vice President, Investor Relations and Corporate Communications at TherapeuticsMD.
  • Prior to TherapeuticsMD, she was Executive Director, Investor Relations and Corporate Communications at Aralez Pharmaceutical, and, before that, served as Senior Director, Investor Relations and Corporate Communications at Auxilum until its acquisition by Endo International plc for $2.6 billion.

Buxton Helmsley Issues Letter to Endo International Plc. Directors, Relating to Financial Disclosures

Retrieved on: 
Martedì, Luglio 26, 2022
Asset Management, Professional Services, Finance, NASDAQ, LLP, Endo International, Doctor of Philosophy, PricewaterhouseCoopers, BHG, Company, Board of directors, Financial adviser

The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, BHG or we), the New York City-based investment advisor to clients with financial interests in Endo International Plc.

Key Points: 
  • The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, BHG or we), the New York City-based investment advisor to clients with financial interests in Endo International Plc.
  • (Endo or the Company) (NASDAQ: ENDP),today issued an open letter to directors of the Company and its financial auditor, PricewaterhouseCoopers LLP, relating to financial disclosures..
  • The full open letter to the Companys directors, along with the private letters between BHG and the Company leading up to this open letter, may be found at: http://www.exposingendo.com/
    Members of the Endo International Plc.
  • About Buxton Helmsley: The Buxton Helmsley Group, Inc. ("BHG") is a premier financial service, asset management and securities research firm, providing an array of services to a diversified group of individuals, corporations, trusts and other entities.

Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs

Retrieved on: 
Lunedì, Luglio 25, 2022
Endo International, R, GLOBE, Omicron, Industry, U.S. Securities and Exchange Commission, Doctor of Philosophy, Maintenance, Research, Risk, Therapy, Safety, COVID-19, Biology, CNTA, Thomas Jefferson University, Company, MD, Senior, Rutgers University, Patient, Nasdaq, Rutgers School of Environmental and Biological Sciences, Haemophilia B, Sanofi, Program, Regulatory affairs, Virology, Wyeth, Pharmaceutical industry, Medical device, Delta, Microbiology

This is a rare opportunity to join a company where each program has the benefit of extraordinary R&D talent and deep industry experience.

Key Points: 
  • This is a rare opportunity to join a company where each program has the benefit of extraordinary R&D talent and deep industry experience.
  • Prior to joining Centessa, Dr. Rotman served as Senior Vice President, Head of Regulatory Affairs at SwanBio Therapeutics, where he was responsible for managing the companys neuromuscular disease gene therapy programs.
  • Dr. Rotman also previously served as Vice President, Head of Regulatory Affairs, Branded Business at Endo Pharmaceuticals where he led the branded global regulatory affairs department in the US and Ireland.
  • Earlier in his career, Dr. Rotman held executive regulatory leadership roles with Indivior, Shire Pharmaceuticals, Sanofi and Wyeth Pharmaceuticals.